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ABSTRACT
Cervical cancer screening using Papanicolaou's smear test has been highly 
effective in reducing death from this disease. However, this test is unaffordable in 
low- and middle-income countries, and its complexity has limited wide-scale uptake. 
Alternative tests, such as visual inspection with acetic acid or Lugol’s iodine and 
human papillomavirus DNA, are sub-optimal in terms of specificity and sensitivity, 
thus sensitive and affordable tests with high specificity for on-site reporting are 
needed. Using proteomics and bioinformatics, we have identified valosin-containing 
protein (VCP) as differentially expressed between normal specimens and those with 
cervical intra-epithelial neoplasia grade 2/3 (CIN2/CIN3+) or worse. VCP-specific 
immunohistochemical staining (validated by a point-of-care technology) provided 
sensitive (93%) and specific (88%) identification of CIN2/CIN3+ and may serve as 
a critical biomarker for cervical-cancer screening. Future efforts will focus on further 
refinements to enhance analytic sensitivity and specificity of our proposed test, as 
well as on prototype development.
INTRODUCTION
More than 80% of invasive cervical cancer cases 
and deaths occur in low- and middle-income countries 
(LMICs). In Africa, more than 50,000 women die from 
cervical cancer and approximately 80,400 are diagnosed 
every year, with incidence variations as high as 5-fold 
within the continent. In the United States, cervical cancer 
incidence rate is 7.7 per 100,000 women in 2012; however, 
prior to the implementation of Papanicolaou (Pap)-based 
screening, cancer incidence rates (per 100,000 females) 
in 10 select metropolitan areas in 1947-1948 were of 
the same order of magnitude (40.1 in whites and 73.1 
in nonwhites) as the highest rates found in East Africa 
today, underscoring the importance of screening and early 
detection [1, 2].
Organized cervical cancer screening programs 
in high-income countries use cervical intra-epithelial 
neoplasia (CIN) as the target lesion. These lesions are 
now known to result from persistent infection with 
oncogenic types of human papillomavirus (HPV) [3]. 
Histopathologically, CIN lesions are subjectively graded 
into 3 categories depending on the severity of the dysplasia; 
CIN1 corresponds to mild dysplasia, CIN2 to moderate 
dysplasia, and CIN3 to severe dysplasia (carcinoma in 
situ) [4]. Pap cytology tests are the most widely used 
screening technique, and women with an abnormal Pap 
test undergo further evaluation using HPV DNA testing 
and/or colposcopy and biopsy to determine the grade of 
CIN or to confirm a diagnosis of invasive cervical cancer. 
The traditional multi-step, laboratory-based screening and 
diagnosis of cervical disease, dependent for its success on 
a reliable recall system, makes the Pap test expensive and 
difficult to sustain in LMICs [5].
Alternative tests to Pap-based cervical cancer 
screening are visual inspection with acetic acid (VIA) 
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and Lugol’s iodine (VILI), and HPV DNA testing. Visual 
inspection has proved to be valuable as a point-of-care 
(POC) test that allows for immediate results and treatment. 
However, it is operator dependent and lacks reliable means 
of quality assurance. In addition, it has low positive 
predictive value (precision), resulting in over treatment 
of a substantial number of women [6, 7]. HPV DNA 
testing has higher sensitivity but lower specificity than 
cytology for the detection of CIN2/3 or worse (CIN2/3+). 
To improve specificity and avoid over-treatment, HPV 
DNA testing is often combined with Pap cytology to 
assist in the identification of women who require referral 
to colposcopy [8]. However, using two screening tests is 
costly, requires sophisticated laboratory infrastructure, 
does not provide immediate results in the same way as 
VIA/VILI screening, and, importantly, may contribute 
substantially to follow-up losses [9].
Simple, affordable, and accurate screening 
modalities are urgently needed to improve coverage 
and effectiveness of cervical cancer prevention efforts 
globally. Ideally, these tests should be able to be 
performed at the  point-of-care (i.e., rapid) and highly 
sensitive and specific for identification of CIN2/3+ in 
order to minimize both false negative and false positive 
results. In this report, we describe the application of 
combined approaches using proteomics and lateral-
flow immunochromatography (LFIC) technology to (1) 
identify markers that accurately identify CIN2/3+ and 
(2) to formulate a simple point-of-care test for cervical 
cancer screening.
Proteomics is a powerful approach to identifying 
diagnostic and prognostic biomarkers. It uses a number of 
protein-analysis techniques that include high-resolution, 
two-dimensional gel electrophoresis (2-DE), mass 
spectrometry (MS), and bioinformatics to determine 
disease-associated biomarkers by observing the expression 
patterns of proteins, thereby distinguishing between 
normal and dysregulated physiological processes [10, 
11]. Proteomic studies have previously been performed 
on cervicovaginal lavage fluid, [12, 13] cervical tissue 
identified as having CIN 2/3 lesions, [14, 15] and cell 
lines, [16] with many biomarkers identified. However, 
none of these biomarkers has been sufficiently accurate for 
cervical cancer screening, and there remains a continuing 
need for sensitive and specific biomarkers that can be 
used to improve screening and diagnosis of pre-invasive 
and invasive cervical cancer, including POC screening 
algorithms.
LFIC is a simple and widely used technique for 
the detection of the presence (or absence) of a target 
analyte in sample mixtures without the need for 
extensive sample preparation steps [17-25]. A lateral-
flow apparatus consisting of a simple membrane with 
a capture zone and pads through which reagents can 
be introduced allows the reaction to be completed 
in a relatively short time (~ 15 minutes) and further 
enables the in-situ separation of unreacted components 
via one-step analysis, a key advantage of this format. 
Additional details of the method are provided in our 
prior published work [18, 24]. In this work we have 
used gold-nanoparticle/avidin-biotin constructs to which 
a number of enzymes can be attached to improve the 
signal generated. This enhanced LFIC system can detect 
proteins at very low concentrations.
The goal of this study was to identify a protein 
biomarker highly sensitive and specific for cervical 
CIN2/CIN3+, and to develop a simple, colorimetric 
test for POC cervical cancer screening in LMICs. To 
this end, we have analyzed the protein-expression 
profiles of normal, pre-invasive, and invasive cervical 
cancer tissues using 2-DE followed by protein detection 
using matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI-TOF-MS) for 
identification of differentially expressed proteins as 
potential biomarkers. The results showed that Valosin-
containing protein (VCP) was significantly expressed 
in CIN2/CIN3 and cervical cancer. VCP was further 
validated by Western blot and immunohistochemistry. 
We then developed a test based on the enhanced lateral-
flow immunochromatography concept to detect the VCP 
in cervical tissues.
RESULTS
2D-PAGE and VCP identification
In this study, we have characterized and compared 
protein expression profiles of adjacent non-neoplastic 
(normal) and CIN2/CIN3, and invasive cervical cancer 
tissues in order to determine proteins with differentially 
altered expression that can be identified as potential 
biomarkers for detection of pre-invasive and invasive 
cervical cancer. 2-DE and image analysis were used to 
compare paired adjacent non-neoplastic, pre-invasive, and 
invasive tumor gels for each individual patient and across 
patients. A two-fold increase or decrease was arbitrarily 
defined as up regulated and down regulated, respectively. 
On average, 1,134 spots were detected per gel. A total of 
512 spots across the normal, CIN2/CIN3, and invasive 
cancer tissues were matched with a match rate of 45%. 
Approximately 144 spots showed expression levels altered 
by a factor of at least 2 in comparison to the normal sample 
as determined by PDQuest. Among these, 85 proteins 
exhibited increased abundance while 59 showed decreased 
abundance. Figure 1 shows representative images of some 
of the spots that were altered in expression, including 
VCP. Statistical analysis using the Bonferroni correction 
(p=0.005) was performed to eliminate possible false 
positives due to multiple, simultaneous comparisons. We 
determined that the VCP protein was significantly altered 
in expression between adjacent non-neoplastic, CIN2/
CIN3, and invasive cervical tissues (p < 0.005).
Oncotarget18789www.impactjournals.com/oncotarget
Validation of VCP in cervical tissues using 
Western blot
Normal, CIN2/CIN3, and invasive cervical cancer 
tissue from 30 patients (10 in each group) were collected, 
washed, and homogenized; equal amounts of protein 
were loaded on SDS-PAGE and expression levels of 
VCP were determined by Western Blot. Figure 2 shows 
that VCP is expressed in CIN2/3 compared to invasive 
cancer. VCP protein was not expressed in the majority 
of normal tissues.
Validation of expression of VCP in cervical 
tissues using immunohistochemistry
To evaluate whether VCP immunoreactivity varies 
between CIN2/CIN3 and invasive cancer and normal 
tissues, samples (3-5 slides per patient) from 152 patients 
were analyzed using immunohistochemical analysis. The 
immunoreactivity of VCP was classified according to the 
score methods described in the Materials and Methods 
section. The immunoreactivity is determined by taking 
into account the intensity of the signal and the percentage 
of VCP-stained cells. Representative photographs of VCP 
staining in invasive cancer, CIN2/3, and normal cervical 
tissues are shown in Figure 3. Strong staining is shown 
in the cytoplasm of cancer tissues. Overall expression of 
VCP was significantly increased in cancer cells compared 
to normal tissues (Figure 3). Additionally, among the 
76 samples classified as “positive” using histopathology 
(CIN2/3+ samples), 71 were correctly marked as positive 
employing the VCP-based method. Out of 44 samples 
scored as “negative,” the VCP approach labeled 5 as 
positive. The inter-rater agreement between two methods 
(Cohen’s κ) was 0.82, which represents robust agreement. 
Assuming that the histopathology-based evaluation 
provided the “ground truth”, the overall accuracy of the 
VCP-based technique was 0.92 (95% CI: 0.85-0.96). The 
observed sensitivity was 0.93 and specificity was 0.87. 
The confusion matrix illustrating the scoring results is 
presented in Table 1.
Lateral-flow immunochromatography (LFIC)
We introduce LFIC as a validation and as an 
onsite screening technique, with the long-term goal of 
developing a POC assay for cervical cancer screening 
using this protein (Figure 4). An enzyme-amplified 
signal was used to detect the selected protein marker, 
VCP, in three types of samples: purified VCP from 
cervical cancer tissues, HeLa-cell lysate, and cervical 
cancer tissue extracts. The photograph of the LFIC strips 
at the detection step is shown in Figure 5. It can be seen 
that, compared with the result from a blank, a limit of 
detection (LOD) as low as 0.21 ng/ml of purified VCP 
was noted. At the same time, a LOD of 28.8 ng/ml in 
tissue extract and 46.3 ng/ml in HeLa cell lysate was 
noted, as shown in Figure 4.
Figure 1: Differentially expressed proteins in cervical carcinoma compared to normal adjacent tissues. Selected areas 
of the spots showing intensity differences between non-neoplastic cervical tissues and neoplastic cervical carcinoma are amplified and 
indicated by arrows.
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DISCUSSION
In this work, we have explored opportunities with 
which to improve cervical cancer screening through 
identification of novel biomarkers and development of a 
model for a simple, POC test for cervical cancer screening. 
To that end, we applied high-throughput proteomic 
technology and bioinformatics in order to assess the 
protein profile differences between normal, CIN2/CIN3, 
and invasive cervical cancerous tissues in order to identify 
proteins that could serve as biomarkers that would be 
sensitive and specific for cervical disease. In addition, 
based on our discovered marker we developed a user-
friendly POC technology, LFIC, which would not be 
reliant on sophisticated laboratory infrastructure or highly 
trained laboratory personnel.
We have used two-dimensional gel electrophoresis 
to separate the proteins from normal, CIN2/CIN3, 
and invasive cancerous cervical tissues. Protein spots 
on the 2-D gels and image analysis showed different 
expression patterns between the different groups of 
tissues studied, indicating protein expressions specific to 
each set of tissues. Statistical comparison of the protein 
expressed between groups identified proteins that were 
significantly decreased, increased, or absent/present in 
some tissues. Using MALDI/MS identification of these 
statistically significantly expressed proteins between 
the groups revealed the following proteins: calreticulin, 
phophodiesterase PDES 16, tumor rejection antigen, 
aldehyde dehydrogenase 1A1, RAsAL1 protein, HSP90, 
phosphoglucomutase 1, vimetin, GRP 78, beta-actin, 
proapo-A-1 protein, DnaK-type molecular chaperone 
HSPA1l, mutant beta-actin, apolipoprotein a-1 precursor, 
albumin, NudE nuclear distribution gene E-like homolog 
1, cyclin-dependent kinase inhibitor 1B, keratin, and 
Valosin-containing protein (VCP, also known as ubiquitin-
dependent molecular chaperone p97).
In this report, we have focused on VCP as a 
potential marker for early detection of cervical cancer. 
We have shown that VCP is significantly overexpressed 
in CIN2/CIN3 and in invasive cancer specimens (p < 
0.005). In addition, we have confirmed VCP expression 
in an independent sample of CIN2/3+ tissues by Western 
blot and immunohistochemistry. Other studies have also 
showed that VCP is associated with HPV transformation. 
HPV progression from benign to transforming infection 
Figure 2: Western Blot validation of VCP proteins detected by proteomics in normal adjacent (N) and cervical 
precancerous and cancer tissues (T). β-actin loading control is shown in the lower panel (N denotes normal tissues (1N, 2N, 3N), 
tumor tissues (2T, 3T, 4T, 5T); precancerous tissues (6T and 7T).
Figure 3: Immunohistochemistry staining of normal (A), CIN3+ (B) and cancerous cervical tissues (C) with antiserum to 
VCP protein. No staining is observed for VCP in normal tissues tested (A) while very intense staining is observed in the cytoplasm of 
CIN3 (B) and tumor cells (C).
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Figure 4: Scheme of enzyme-enhanced LFIC for VCP detection. Biotinylated gold nanoparticles tethered with streptavidin-
bearing HRP at the capture site in the lateral flow strip to generate a signal upon interaction with TMB.
Figure 5: Photographic results of LFIA detection from blank (A), 0.21 ng/ml purified VCP (B), 28.8 ng/ml tissue extractive 
(C), and 46.3 ng/ml HeLa lysate (D).
Table 1: Sensitivity and specificity of VCP in detecting cervical lesions
Histopathology scoring
positive negative
VCP immunochemistry scoring
positive 71 5
negative 5 39
Oncotarget18792www.impactjournals.com/oncotarget
is characterized by an increase of HPV E6/E7 mRNA and 
protein expression, [26] and VCP has been shown to be 
regulated by the HPV E6 gene through the E6-E6AP-
PTPN3 network [27]. Furthermore, a high correlation 
between elevated expression of VCP and progression, 
prognosis, and metastatic potential in pancreatic, hepatic, 
esophageal, prostate, and colorectal cancers has previously 
been reported [28-33].
VCP is a member of the AAA class of ATPases 
found throughout the body and has a wide variety of 
functions within cells. It is involved in cycle regulation, 
nuclear envelope formation, Golgi biogenesis, DNA 
repair, gene expression, cell growth, and the ubiquitin 
proteasome system [34]. VCP mediates endoplasmic 
reticulum (ER)-associated degradation, a process by 
which misfolded proteins localized in the ER lumen or 
membrane are eliminated through its interaction with 
several accessory proteins and cofactors. Upon the 
ubiquitination of misfolded proteins, VCP is thought 
to extract the targeted proteins from the ER in an ATP-
dependent manner maintain their misfolded state until they 
can be degraded by the cellular proteasome machinery 
[35] or the aggresome-autophagy pathway [36].
Although distributed in normal cells and needed for 
many physiological cell processes, p97/VCP ubiquitin is 
overexpressed in malignant cells in many different types 
of cancer [28-31, 33]. This could be explained by the fact 
that VCP is up-regulated by damage-induced protein stress 
signals that are elevated in cancer cells and that it helps 
in the clearance of abundant, misfolded/aggregate-prone, 
and potentially toxic proteins from malignant cells and 
facilitates their survival [37]. Lack of p97/VCP activity 
results in accumulation of misfolded, polyubiquitinated 
proteins leading to apoptosis, as occurs in non-malignant 
cells.
In order to address some of the limitations in clinical 
performance and scalability of traditional Pap and/or HPV 
DNA—based cervical cancer screening, several biomarkers 
are now commercially available. These include Pre-Tec 
Proofer (Proofer; Norchip AS, Norway) [38]; APTIMA 
HPV for detection of E6/E7 mRNA (Hologic, San Diego, 
CA) [39]; CINtec cytology for detection of P16ink4a protein 
(Roche Laboratories, Indianapolis, IN) [40]; and ProEX C 
for detection of topoisomerase IIA and minichromosome 
maintenance protein 2 (Becton Dickinson, Franklin 
Lakes, NJ) [41]. However, these biomarkers all suffer 
heterogeneity in the interpretation of results and non-
uniformity in determination of end points.
In our initial laboratory experiments, we have found 
that VCP is highly sensitive (93%) and specific (89%) 
for CIN2/3+. We have also demonstrated the overall 
accuracy to be between 85% and 96% (α= 0.05). Based 
on these results, we have developed an assay prototype 
based on LFIC technology. The LFIC assay is easy 
to use and interpret, with a turn-around time of ~ 15 
minutes. As our approach utilizes gold nanoparticles 
conjugated with antibody and horseradish peroxidase 
as probes, signals are observable by the naked eye. The 
simplicity of this assay would allow it to be incorporated 
into POC screening strategies, including in LMICs, as 
we anticipate that healthcare personnel with disparate 
backgrounds and training would be able to use the test 
safely and effectively. However, additional work is needed 
to optimize the assay for alternative sample types (e.g., 
cervical swabs, cervicovaginal lavage specimens, and 
PreservCyt specimens) and larger studies are needed for 
robust clinical validation.
In conclusion, our data demonstrate that VCP-
specific immunohistochemical staining provides a 
sensitive and specific identification of CIN2/3+ in cervical 
tissue specimens and that VCP may represent a useful 
marker for screening and early detection of pre-invasive 
and invasive cervical disease. We have also demonstrated 
proof-of-concept for a POC molecular assay for cervical 
screening based on LFIC. Future efforts will focus on 
further improvements in the technology with respect to 
analytic sensitivity and specificity across sample types, 
as well as prototype development for larger clinical 
performance evaluations.
MATERIALS AND METHODS
Chemicals and reagents
Urea, trypsin, coomassie brilliant blue r-250, 
dithiothreitol (DTT), glycerol, glacial acetic acid, alpha-
cyano-4-hydroxycinnamic acid (CHCA), acetonitrile 
(AcN), sodium citrate, sodium carbonate, HAuCl4, 
casein (sodium salt type), Ponceau S, and tetramethyl 
benzidine (TMB) were purchased from Sigma (St Louis, 
MO). ReadyStrip was purchased from Bio-Rad (IPG 
strip pH 4-7; Bio-Rad). VCP antibody was obtained 
from Abcam (Cambridge, MA). Monoclonal p97/VCP 
antibody (H0007415-M15 and H0007415-M18) was 
purchased from Abnova (Taipei, Taiwan). Sulfo-NHS-
LC-biotin and streptavidin poly-HRP were purchased 
from Pierce (Rockford, IL). Biotinylated goat anti-mouse 
secondary antibody (GAM IgG) conjugated to HRP was 
purchased from Dakocytomation (Carpinteria, CA). Mayer 
hematoxylin was purchased from Richard-Allan Scientific 
(Kalamazoo, MI). Immunohistochemistry reagents were 
all purchased from Biocare Medical (Concord, CA).
Human tissue samples and tissue microarray
Fresh-frozen tissues (n=30) and formalin-fixed 
paraffin-embedded (FFPE) cervical tissues (n=152) were 
obtained from women who underwent hysterectomy for 
invasive cervical cancer or benign conditions at Grady 
Hospital, Atlanta, GA, and Indiana University School 
of Medicine, Indianapolis, IN. Sample collection and 
handling were performed under the approval of the Emory 
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University, Indiana University, and Purdue University 
Institutional Review Boards. Participation was offered 
to all patients undergoing hysterectomy, and consent 
was obtained. Prior to removal of tissues for the study, 
all patients were given a Pap smear test, and if necessary, 
underwent colposcopy and cervical biopsies in accordance 
with standard clinical recommendations. Additional FFPE 
tissues (n=5 cases; 5 slides each) were obtained from 
Indiana University School of Medicine. Tissue microarray 
slides each containing 24 tissue sections were purchased 
from US Biomax Inc (Rockville, MD), 16 of which were 
normal cervical tissues. Of the 30 fresh-frozen tissues, 
10 cervical samples were obtained from patients with 
invasive squamous-cell carcinoma, 10 were non-neoplastic 
adjacent tissues, and 10 were from patients with pre-
invasive lesions (i.e., CIN2/CIN3). The 120 FFPE tissues 
included 34 malignant samples, 35 normal tissues, 13 from 
CIN1 lesions, 10 from CIN2, and 28 from CIN3.
Protein extraction
Cervical tissues weighing approximately 500 mg 
were quickly thawed and washed three times in ice-cold 
“salt-free” phosphate buffer (8 mM Na2HPO4, 2 mM 
KH2PO4) to remove any residual blood. Samples were cut 
into small pieces and chilled in 10 mL lysis buffer (salt-
free phosphate buffer pH 7.5, 0.5% Triton X-100, 1 mM 
PMSF, 15 mg/mL aprotinin, 10 mg/mL leupeptin, 10 mg/
mL pepstatin, 100 mg/mL DNase 1, 25 mg/mL RNase A, 
5 mM MgCl2). Tissues were homogenized on ice using an 
electrical tissue homogenizer, and then centrifuged at 20 g 
for 15 minutes at 37° C. The supernatants were transferred 
to new tubes and protein concentration was determined 
using an Amersham 2D Quant kit (GE Healthcare Bio-
Sciences, Piscataway, NJ). Protein from the above tissue 
lysates (2.5 mg) was transferred into glass tubes, and 
precipitated using TCA/acetone precipitation. About 2% 
carrier ampholyte (pH 8–10.5) was added to the pellet 
solution (0.4 mL solution containing 9 M urea, 4% Igepal, 
and 1% DTT) and mixed thoroughly.
2-DE and image analysis
200 mg of protein was used to perform 2-DE 
according to the technique described by Li et al, [42]. 
The protein samples from adjacent non-neoplastic (n=10), 
CIN2/CIN3 (n=10), and invasive carcinoma (n=10) 
were analyzed in triplicate, in addition to pooled protein 
samples for all carcinomas, and pooled protein samples 
for all adjacent non-neoplastic tissues. Pooled samples 
were mixed proportionally so as not to compromise low-
abundant proteins. Two hundred micrograms protein from 
each sample (individual or pooled samples) was placed on 
first-dimension IEF tube gels containing 3.3% acrylamide, 
9 M urea, 2% Igepal CA-630, and 2% ampholyte (BDH 
pH 4–8). The gels were produced in the laboratory using 
the LSB Angelique™ Gradient Gel Casting System. The 
IEF gels were then run simultaneously using progressively 
increasing voltage (500V for 1 hour, 750V for 1 hour, 
1000V for 1 hour, and 1400 V for 18.75 hour) for a total 
of 28 500 Vh at room temperature. Subsequently, the 
focused gels were loaded directly onto 2-D slab gels 
with a linear gradient of 11–19% without equilibration. 
The slab gels were then run in parallel in a Protean Plus 
Dodeca Cell (Bio-Rad, Hercules, California) at 87°C 
for 18 h at 160 V. The slab gels were fixed in 1.5 L of 
fixing solution (50% ethanol and 2% phosphoric acid) 
overnight and covered (6 gels/covered box). Gels were 
then washed and subsequently transferred to 1.5 L of 
staining solution (30% methanol, 17% ammonium 
sulfate, and 3% phosphoric acid) for 1 h, followed by the 
addition of 1g powdered CBB G-250 stain for 96 h. The 
gels were washed with water and scanned at 95.3-micron 
resolution using a Bio-Rad GS-800 Calibrated Imaging 
Densitometer. The resulting images were analyzed using 
PDQuest software (Bio-Rad, V7.1) on a PC with Windows 
2000. The background was subtracted and the peaks for 
the protein spots were located and counted. Numerous 
proteins that were uniformly expressed in all gels were 
used as landmarks to facilitate rapid gel matching. Gels 
were normalized using PDQuest software. Statistical 
comparisons between individual protein abundances 
were conducted by calculation of Student’s t-test using 
the built-in function within PDQuest. In addition, the 
raw data for each protein spot were exported to Excel 
(Microsoft, Redmond, WA) for further statistical analysis 
(see statistical analysis section below).
Peptide mass fingerprinting
Unique protein spots between each of the sample 
groups were cut from the gel robotically using 2D 
Protein Spot Cutter (Bio-Rad) and placed in a 96-well 
plate. Pieces of blank gels whose mass lists were used as 
background reference were processed along with other 
samples. The excised protein spots were destained with 
50 mM ammonium bicarbonate, 50% ACN, and 100% 
ACN, respectively. Samples were reduced with 10 mM 
DTT, alkylated with 55 mM iodoacetamide, and washed 
first with 50 mM ammonium bicarbonate and then with 
100% ACN. Promega sequence-grade trypsin (10 mL) 
(12.5 ng/mL in 50 mM ammonium bicarbonate) was 
added to each sample and incubated overnight at 37° C. 
The resulting peptides were extracted with 60% ACN 
and 0.1% TFA, 5% formic acid, and 80% ACN and 0.1% 
TFA. The peptide extract (1 mL) was mixed with 1 mL of 
matrix (10 mg/mL CHCA and 0.05% TFA), placed onto 
each corresponding position on the MALDI target plate, 
air-dried, and then washed with 10 mL 0.1% TFA for 10 
seconds to desalt. The samples were analyzed by MALDI-
TOF-MS using M@LDI System (Micromass, UK). Prior 
to data collection, the instrument was calibrated using 
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peptide standards. Mass lists of all the determined samples 
were generated by Protein Lynx (Micromass) and filtered 
against the blank control mass list to eliminate background 
peaks, using in-house software. The filtered mass lists 
were submitted to Profound Peptide Mass Database for 
further analysis. The parameters were as follows: no more 
than one tryptic miscleavage allowed, cysteine searched 
as carboxamidomethyl cysteine (157.0215 Da), 50 ppm 
peptide tolerance and 0.2 Da mass tolerances. A Z-score 
of 1.65, was obtained. This score corresponds to the 
95th percentile and is used as a threshold for a positive 
identification.
Western blot analysis
Protein immunoblotting was used to verify and 
validate the proteomic biomarker candidates. Frozen tissue 
samples were immersed in lysis buffer containing 1 M 
Tris (pH 7.6), 5 M sodium chloride (NaCl), 10% sodium 
azide (NaN3), 200 mM EDTA, and 10% Triton X-100. 
Tissues were homogenized and sonicated on ice and then 
centrifuged at 10,000 g for 10 minutes. The supernatants 
were transferred to new tubes and protein concentrations 
were determined with the bicinchoninic acid (BCA) protein 
assay (Thermo Fisher Scientific, Rockford, IL). Equal 
amounts of protein (1μg per lane) were electrophoresed 
by 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) under reducing conditions 
and then transferred onto a pure nitrocellulose blotting 
membrane (Bio-Rad Laboratories, Hercules, CA). The 
transfer of protein and equal loading in all lanes was 
verified using reversible staining with Ponceau S (Sigma 
Chemical, St. Louis, MO) on the NC and β-actin. The 
membranes were blocked using 5% dry non-fat milk in 
TBST solution for 30 minutes. Blots were incubated with 
Valosin-containing protein (VCP) antiserum (Abcam) 
at a dilution of 1:4000 for 1 h at room temperature. This 
was followed by the application of biotinylated goat anti-
mouse secondary antibody (GAM IgG) conjugated to 
HRP (Dakocytomation, Carpinteria, CA). The presence 
of VCP was detected by chemoluminescence, utilizing 
a gel-documentation system? Antibody specificity was 
determined by incubating parallel membranes with and 
without VCP antibody.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections 
from the cervical biopsies were processed for VCP 
immunohistochemistry according to the Biocare 
protocol using a MACH-4 detection system. Briefly, 
slides containing tissue sections were deparaffinized in 
xylene and hydrated in graded concentrations of ethanol. 
Endogenous peroxidase activity was quenched for 10 
minutes (using 0.3% H2O2) and epitope retrieval was 
performed by placing the slides in Diva antigen-retrieval 
solution (Biocare, Concord, CA) for 30 minutes at 95° C 
in a water bath. Sections were then incubated in primary 
antibody, monoclonal VCP (1:1, 000 dilution; Abcam, 
Cambridge, MA), for 30 minutes, followed by 15 minutes 
in mouse probe and 10 minutes in polymer, and visualized 
by incubation for 5 minutes in 3,3' diaminobenzidine 
(DAB). The sections were then washed and immersed in 
Mayer hematoxylin (Richard-Allan Scientific, Kalamazoo, 
MI) for 5 minutes. Finally, the slides were washed and 
gradually dehydrated and cover slipped after addition of 
one drop of permanent mounting medium.
We have assessed VCP immunoreactivity semi-
quantitatively based on the staining intensity and 
percentage of stained cells. Expression of VCP was scored 
as 0 (<5% cells positive); 1+ (6–25% cells positive); 2+ 
(26–50% cells positive), and 3+ (<50% cells positive). 
HeLa cells were used as positive controls. VCP staining 
intensity was scored as “0” (no staining), “1” (low 
staining), “2” (medium staining), and “3” (high staining).
Lateral-flow immunochromatography assay
The gold nanoparticles (GNPs) used for the probes 
were synthesized based on the method reported by Frens 
et al. [43]. GNP probes for LFIC were prepared based on 
previously published reports [17, 24]. Briefly, 1 ml GNPs 
was added to 1 μl of 0.5 M sodium carbonate, 100 μl of 
10 mM phosphate buffer (pH 7.4), and 10 μg monoclonal 
p97/VCP antibody (H0007415-M18), and the obtained 
solution was kept under gentle stirring for 2 hours. Then 
122 μl of 5% (w/v) casein (10 mM phosphate buffer 
solution, pH 7.4) was injected and the obtained solution 
was gently stirred at room temperature overnight for 
blocking. Centrifugation at 10,000 rpm for 10 minutes was 
performed to remove unbound molecules; the precipitate 
was washed and redispersed in 1 ml of 10 mM phosphate 
buffer solution, followed by mixing with 10 μg of sulfo-
NHS-LC-biotin. After shaking for 1 hour, 100 μl of 5% 
(w/v) casein in 10 mM phosphate buffer was added and 
the obtained solution was gently stirred for 1 hour. The 
obtained product was centrifuged, washed with 10 mM 
PBS, and redispersed in 100 μl of 10 mM PBS buffer with 
5% (w/v) casein.
The strips for Lateral Flow immunochromatography 
(LFIC) detection were prepared with 0.2 μg monoclonal 
p97/VCP antibody (H0007415-M15) fixed on the 
nitrocellulose membrane and dried at 37° C. Detection of 
the target was performed following the reported approach 
[24]. During LFIC detection, the sample absorbent pad of 
the strip was loaded with 100 μl sample mixed with 0.2 μl 
GNP probe and 0.2 μl streptavidin poly-HRP to initiate the 
immunoreaction between the GNP probe-labeled VCP and 
the VCP antibody (p97/VCP antibody, H0007415-M15) 
fixed on LFIC strip. After 15 minutes, the strips were fixed 
with 2 more absorbent pads in the cross-flow direction and 
60 μl water was added to wash off the unbound reactants 
on the strip during cross-flow. 30 μl TMB was added to 
one of the additive pads for signal generation and then 60 
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μl water was used to stop the reaction. The color signals 
observed on the LFIC strips were utilized to quantify the 
VCP in the samples based on the developed calibration 
plot.
Statistical analysis
For a selected spot in the gels, a two-sample paired 
t-test was used to compare invasive carcinomas and their 
paired non-neoplastic tissues or pre-invasive lesions. 
The analyzed variable was the log of the spot intensity. 
If the spot was not present, ‘0’ was used to signify the 
lack of intensity. Bonferroni correction was used to adjust 
for multiple comparisons, where the cut-off value was p 
= 0.005. Bonferroni correction is a multiple-comparison 
correction used when several dependent or independent 
statistical tests are being performed simultaneously. Spots 
that were noted to be significantly different between the 
three issues types were selected for further consideration 
as potential biomarkers.
The observed VCP immunoreactivity rated as 
described above was compared to the results of established 
histopathology-based diagnosis. For the purpose of this 
comparison a binary classification scheme was created: 
VCP responses rated 2+ and 3+ were categorized as 
“positive,” whereas those rated 0 and 1+ were considered 
negative. The histopathological samples scored as CIN2 
or CIN3 or cancer were considered “positive,” and 
samples designated as “normal” or CIN1 were considered 
“negative.” The results were represented using a confusion 
matrix (or contingency table), and we calculated overall 
accuracy with a 95% confidence interval, Cohen κ, 
sensitivity, and specificity of VCP for CIN2/3+.
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